The Kidney Cancer Association (KCA) will partner with Topline Bio, LLC for a new era of digital education and storytelling with and for healthcare professionals treating kidney cancer as well as patients and families impacted by the disease.
“This partnership solidifies our ability to create the sort of content that can revolutionize communication in our space by bringing easily digestible scientific and clinical information to practicing clinicians and patients alike,” said Henry Haringsma, Partner and Head of Scientific Content of Topline Bio. “This collaboration allows us to shine a light on kidney cancer and to tell the stories of hope and survivorship. We are grateful for the commitment and shared vision put forth by both our team and our partners at the KCA.”
“We are proud to join with Topline Bio and bring the kidney cancer community an exciting new media series to educate practicing clinicians about new advances in kidney cancer and make patients aware of the critical kidney cancer information they should know in order to be the best advocates they can be for their care,” said Dr. Salvatore La Rosa, KCA’s Chief Scientific Officer. “With a foundation of established kidney cancer expertise, working with Topline Bio to continue innovating on new formats and modalities to share stories of progress and hope will help us reach wider communities of people impacted by kidney cancer who need this crucial information.”
About Kidney Cancer
Kidney cancer is one of the 10 most common cancers affecting people in the US and the 14th most common cancer in the world. Over half a million people live with kidney cancer in the US with nearly 82,000 new cases expected to be diagnosed in 2024 and over 14,000 deaths.
In the past decade, options for kidney cancer care and treatment have expanded significantly through targeted therapies, the advent of immunotherapies, which activate the body’s own immune system to target and destroy cancerous cells, and a growing understanding of the molecular makeup and behavior of kidney tumors.
However, much remains unknown including details about the various types of kidney cancer – especially rare and aggressive variants – and who will respond best to specific treatments. Collaborations between professional and advocate communities are a key path to accelerating discovery and making optimal care accessible to patients and families.
###
About Topline Bio, LLC.
Topline Bio is a scientific clinical insights and digital media communications company, established in 2022, committed to bridging the gap between academic medicine and community treaters. Topline Bio is dedicated to working in the oncology space, and genitourinary and women’s cancers and has emerged as a market disruptor in the medical communications agency world.
Topline Bio collaborates with societies, organizations, key opinion leaders, and experts to collect clinical insights and develop high-quality video content
To learn more, visit: https://www.toplinebio.com/
About The Kidney Cancer Association
The Kidney Cancer Association is a global community dedicated to serving and empowering patients and caregivers, and leading change through advocacy, research, and education in order to be the universal leader in finding the cure for kidney cancer. Founded in 1990 by Eugene P. Schonfeld and a small group of patients and doctors in Chicago, Illinois, the KCA has grown into an international non-profit organization based in Houston, Texas. The KCA promotes scientific advances through two annual research symposiums and a robust grant program, participates in legislative advocacy, and seeks to be a source of education and resources for patients, caregivers, and anyone impacted by kidney cancer.
Media Contact
Radha Chitale
Senior Director of Communications
847-332-5573 | [email protected]
